Workshop 6 - Brainstorming & Policy Development session: Training, information and education of MDs
"Feedback from the 15 National Conferences"
Christel Nourissier, EURORDIS
Workshop 7 - Brainstorming & Policy Development session: Prevention
"Folic acid prevents neural tubes defect"
Mrs Eli Skattebu, Norwegian Association for Spina Bifida and Hydrocephalus (RHF)"
Kim Hannisdal, BayerAB, Sweden
Workshop 7 - Brainstorming & Policy Development session: Prevention
"Presentation of the International Federation for Spina
Bifida and Hydrocephalus’ primary prevention study"
Pierre Mertens, International Federation for Spina Bifida and Hydrocephalus (IF)
It may be the political and economic leader of Europe, but when it comes to the global obesity epidemic, Germany takes a decidedly relaxed attitude compared with its neighbours.
The presentation summarizes the final output of a major project that was commissioned to address exposure to biological agents in the workplace and the related health effects. The study included a scientific literature review, interviews with experts, focus group sessions and a stakeholder workshop.
The BURQOL-RD project aims to develop a model to quantify the socio-economic burden and health-related quality of life of rare disease patients and caregivers in Europe. The 3-year project will measure these impacts for 10 rare diseases across 8 countries. Associated partners will carry out core activities while collaborating partners provide specific contributions. The project will generate standardized tools, conduct a pilot study, and refine the tools for ongoing rare disease assessment and monitoring across Europe.
The document discusses the history of efforts by the German Association of Sarcoidosis Patients and their relatives (DSV) to introduce rare diseases like sarcoidosis to medical students' education. It describes DSV's attempts since the 1980s to provide continuing education for doctors and a few successful initiatives to organize student training sessions with medical experts and sarcoidosis patients. The document concludes by outlining preliminary thoughts and proposed contents for a training package on rare diseases that could accompany future student training sessions.
Workshop 6 - Brainstorming & Policy Development session: Training, information and education of MDs
"Feedback from the 15 National Conferences"
Christel Nourissier, EURORDIS
Workshop 7 - Brainstorming & Policy Development session: Prevention
"Folic acid prevents neural tubes defect"
Mrs Eli Skattebu, Norwegian Association for Spina Bifida and Hydrocephalus (RHF)"
Kim Hannisdal, BayerAB, Sweden
Workshop 7 - Brainstorming & Policy Development session: Prevention
"Presentation of the International Federation for Spina
Bifida and Hydrocephalus’ primary prevention study"
Pierre Mertens, International Federation for Spina Bifida and Hydrocephalus (IF)
It may be the political and economic leader of Europe, but when it comes to the global obesity epidemic, Germany takes a decidedly relaxed attitude compared with its neighbours.
The presentation summarizes the final output of a major project that was commissioned to address exposure to biological agents in the workplace and the related health effects. The study included a scientific literature review, interviews with experts, focus group sessions and a stakeholder workshop.
The BURQOL-RD project aims to develop a model to quantify the socio-economic burden and health-related quality of life of rare disease patients and caregivers in Europe. The 3-year project will measure these impacts for 10 rare diseases across 8 countries. Associated partners will carry out core activities while collaborating partners provide specific contributions. The project will generate standardized tools, conduct a pilot study, and refine the tools for ongoing rare disease assessment and monitoring across Europe.
The document discusses the history of efforts by the German Association of Sarcoidosis Patients and their relatives (DSV) to introduce rare diseases like sarcoidosis to medical students' education. It describes DSV's attempts since the 1980s to provide continuing education for doctors and a few successful initiatives to organize student training sessions with medical experts and sarcoidosis patients. The document concludes by outlining preliminary thoughts and proposed contents for a training package on rare diseases that could accompany future student training sessions.
Mr. Mika Salminen, SHARP JA Coordinator, Director, Department of Health Security, Finnish Institute for Health and Welfare (THL), at One Health Security Conference, 14-15 Oct 2019, THL, Helsinki
Gesamt publikation understanding the pharmaceutical care concept and applying...nuretampan
This document provides an overview of pharmaceutical care initiatives in Europe based on a scoping exercise conducted by Gesundheit Österreich GmbH. It summarizes the results of a literature review and case studies of pharmaceutical care practices in Austria and Portugal. The literature shows long-standing traditions of pharmaceutical services in some Western European countries but less advanced implementation in Central and Eastern Europe. Disease-specific programs for conditions like heart disease and asthma are common. International projects like the Pharmaceutical Care Network Europe coordinate joint initiatives. The case studies describe specific programs in Austria like medication safety reviews and public health days, and comprehensive care programs in Portugal. Several disease areas and potential indicators for evaluating pharmaceutical care are also discussed.
The document summarizes key points from a speech given by the WHO Regional Director for Europe on health challenges in the European region and strategies to address them. The main points are:
1) There are significant health inequities within and between countries in the European region in terms of life expectancy and healthy life expectancy. Nordic countries have some of the highest rates.
2) Investing in public health, disease prevention, and addressing social determinants of health through intersectoral policies can help reduce inequities and improve population health outcomes.
3) The Health 2020 policy framework and examples from countries like Norway that have strengthened public health infrastructure and implemented intersectoral governance approaches provide guidance for addressing challenges and closing
The document describes various alert and sentinel systems for identifying work-related diseases. It discusses compensation-based systems, systems for data collection and statistics, and sentinel systems. Compensation-based systems collect data for compensation purposes and are usually mandatory. Systems for data collection aim to measure trends in occupational safety and health. Sentinel systems monitor work-related diseases and see each case as a potential signal, with some focusing on specific exposures or diseases. The document provides examples of different types of systems from several European countries.
This publication is the result of a two-year project to publish European standards in drug prevention, co-funded by the European Commission (EC) (60 %) and the respective project partner organisations (40 %). The standards were developed by the Prevention Standards Partnership, a multi-disciplinary and multi-sectoral collaboration of seven organisations across Europe, led by Dr Harry Sumnall andAngelina Brotherhood of the Centre for Public Health at Liverpool John Moores University (LJMU), UK, who are also the authors of this publication. European Union (EU) policy, such as the EU drugs action plans for 2005-08 and 2009-12, has expressed an intention to develop and implement best practice in drug prevention, but so far has not been able to provide o reference framework on how to do this. Guidance on drug prevention interventions is available in some Member States of the EU, but it varies in terms of its content, methodological rigour, and its applicability to the wider European context. In response to this situation, this project aimed to provide a commonly agreed reference framework that could help improve the state of drug prevention in the EU
The document outlines the European Union's actions and priorities in the field of rare diseases. Key points include:
- Establishing a definition of rare diseases and improving disease classification.
- Supporting national plans and strategies for rare diseases in EU member states.
- Developing networks of centers of expertise and establishing European reference networks.
- Improving access to information, diagnosis, treatment and care for rare disease patients across Europe.
- Accelerating research and ensuring access to orphan drugs for rare diseases.
Labour and social protection policies and primary health careHealth and Labour
Presentation by dr. Igor FEDOTOV, Coordinator, Occupational and Environmental Health, ILO Progamme SAFEWORK,Geneva, at the WHO/TNO/Dutchgovernment Congres 'Connecting Health and Labour' 29 - 1 December 2012
Presentation given by Elke Schneider (EU-OSHA) to the Conference 'Europe at a crossroads. Which way to quality jobs and prosperity?' held under the joint auspices of the European Trade Union Confederation (ETUC) and the European Trade Union Institute (ETUI) held in Brussels on 24-26 September 2014.
The document discusses the European Observatory on Health Systems and Policies, outlining its central principles, partnerships, governance, and core mission. The key points are:
1. The Observatory's central principles are to provide comparative analysis of health systems and policies, bridge the gap between evidence and policymaker needs, and develop practical policy options.
2. Partnerships with organizations like WHO and academic institutions are key to bridging this gap and ensuring research is relevant and accessible to policymakers.
3. Governance involves steering committees, independent academic directors, and a dedicated secretariat overseen by WHO.
4. The core mission is supporting evidence-based health policymaking through comprehensive analysis of European health systems,
The document discusses the European Observatory on Health Systems and Policies, outlining its central principles, partnerships, governance, and core mission. The key points are:
1. The Observatory's central principles are to provide comparative analysis of health systems and policies, bridge the gap between evidence and policymaker needs, and develop practical policy options.
2. Partnerships with organizations like WHO and academic institutions are key to bridging this gap and ensuring research is relevant and accessible to policymakers.
3. Governance involves steering committees, independent academic directors, and a dedicated secretariat to ensure credibility and quality.
4. The core mission is supporting evidence-based health policymaking through comprehensive analysis of European health systems
This document provides guidelines for workplace interventions to address psychoactive substance use. It recommends comprehensive interventions at workplaces that promote health, prevent accidents, and support employees. Interventions should include raising awareness, assessing workplace policies, brief interventions, referral systems, testing when appropriate, and ensuring confidentiality. The workplace is a convenient access point for health promotion given that most adults spend significant time at work. Prevention, identification, counseling, treatment and rehabilitation should be part of a systematic approach to address psychoactive substance harms in a way that also benefits families and communities.
The document discusses the regulatory environment for medicines in Ireland and Europe. It outlines how the Irish Medicines Board operates within the European system, providing resources to the European Medicines Agency and participating in evaluation, supervision, and inspection. It also discusses the IMB's international involvement, including partnerships with other agencies and participation in initiatives to enhance public health protection globally. Finally, it evaluates factors that contribute to the IMB becoming a "world-class" regulatory body.
The German Plan for Rare Diseases is a work in progress to improve care for those living with rare diseases in Germany. The document discusses that currently, rare diseases receive insufficient attention and care is fragmented across different healthcare sectors. It recommends developing a national coalition and plan to establish centers of expertise, improve guidelines and care coordination, and increase European collaboration. This coalition, called NAMSE, has begun work through working groups to develop a national plan and improve patient information, diagnostics, treatment guidelines and quality of care for those with rare diseases.
The document summarizes the development of national initiatives and European policies for rare diseases over the past few decades. It outlines key events and documents that have recognized rare diseases as a public health priority in Europe. These include the establishment of national plans and centers of expertise in many European countries between the 1980s-2000s, as well as European regulations, programs, and networks to support research, care, and access to orphan drugs. It discusses ongoing challenges and priorities for further developing strategies and cross-national collaboration to improve quality of life for those affected by rare diseases.
The document summarizes the development of national initiatives and European policies for rare diseases over the past few decades. It outlines key events and documents that have recognized rare diseases as a public health priority in Europe requiring transnational cooperation. These include the establishment of national plans and centers of expertise in many European countries from the 1980s onward, as well as European regulations, recommendations, and programs to support research, care coordination, and patient organizations. However, it notes ongoing challenges around decentralization, resources, and sustainability that require continued supportive policies.
The European Commission views patient safety as a priority and has taken several steps to promote it. These include establishing a patient safety working group, funding projects like EUNetPaS, and adopting a recommendation that encourages member states to develop national patient safety policies, empower patients, establish reporting systems, promote a culture of safety, and conduct research. While progress has been made, more work is still needed at the member state level, and the EU aims to play a supportive role through knowledge sharing, best practices, and continued coordination across Europe.
This document advertises the 10th annual conference of the Guidelines International Network (G-I-N) being held in Berlin. The conference will celebrate G-I-N's 10 years of international collaboration on clinical practice guidelines and discuss lessons learned and future visions. Plenary sessions will address topics like guideline methodology, the effects of guidelines on healthcare quality and outcomes, and patient involvement in guideline development. Pre-conference courses are also offered on guideline development, implementation, the GRADE approach, and health economics. A German language symposium will discuss guideline-related issues in German-speaking countries.
Thematic Platform for Emergency and Disaster Risk Management Health and the ...Global Risk Forum GRFDavos
Presentation at the Consultion Day event about: Scientific and Technical Platforms / Networks: Achievements and Future Goals during the Global Platform for Disaster Risk Reduction GPDRR 2013 in Geneva
Mr. Mika Salminen, SHARP JA Coordinator, Director, Department of Health Security, Finnish Institute for Health and Welfare (THL), at One Health Security Conference, 14-15 Oct 2019, THL, Helsinki
Gesamt publikation understanding the pharmaceutical care concept and applying...nuretampan
This document provides an overview of pharmaceutical care initiatives in Europe based on a scoping exercise conducted by Gesundheit Österreich GmbH. It summarizes the results of a literature review and case studies of pharmaceutical care practices in Austria and Portugal. The literature shows long-standing traditions of pharmaceutical services in some Western European countries but less advanced implementation in Central and Eastern Europe. Disease-specific programs for conditions like heart disease and asthma are common. International projects like the Pharmaceutical Care Network Europe coordinate joint initiatives. The case studies describe specific programs in Austria like medication safety reviews and public health days, and comprehensive care programs in Portugal. Several disease areas and potential indicators for evaluating pharmaceutical care are also discussed.
The document summarizes key points from a speech given by the WHO Regional Director for Europe on health challenges in the European region and strategies to address them. The main points are:
1) There are significant health inequities within and between countries in the European region in terms of life expectancy and healthy life expectancy. Nordic countries have some of the highest rates.
2) Investing in public health, disease prevention, and addressing social determinants of health through intersectoral policies can help reduce inequities and improve population health outcomes.
3) The Health 2020 policy framework and examples from countries like Norway that have strengthened public health infrastructure and implemented intersectoral governance approaches provide guidance for addressing challenges and closing
The document describes various alert and sentinel systems for identifying work-related diseases. It discusses compensation-based systems, systems for data collection and statistics, and sentinel systems. Compensation-based systems collect data for compensation purposes and are usually mandatory. Systems for data collection aim to measure trends in occupational safety and health. Sentinel systems monitor work-related diseases and see each case as a potential signal, with some focusing on specific exposures or diseases. The document provides examples of different types of systems from several European countries.
This publication is the result of a two-year project to publish European standards in drug prevention, co-funded by the European Commission (EC) (60 %) and the respective project partner organisations (40 %). The standards were developed by the Prevention Standards Partnership, a multi-disciplinary and multi-sectoral collaboration of seven organisations across Europe, led by Dr Harry Sumnall andAngelina Brotherhood of the Centre for Public Health at Liverpool John Moores University (LJMU), UK, who are also the authors of this publication. European Union (EU) policy, such as the EU drugs action plans for 2005-08 and 2009-12, has expressed an intention to develop and implement best practice in drug prevention, but so far has not been able to provide o reference framework on how to do this. Guidance on drug prevention interventions is available in some Member States of the EU, but it varies in terms of its content, methodological rigour, and its applicability to the wider European context. In response to this situation, this project aimed to provide a commonly agreed reference framework that could help improve the state of drug prevention in the EU
The document outlines the European Union's actions and priorities in the field of rare diseases. Key points include:
- Establishing a definition of rare diseases and improving disease classification.
- Supporting national plans and strategies for rare diseases in EU member states.
- Developing networks of centers of expertise and establishing European reference networks.
- Improving access to information, diagnosis, treatment and care for rare disease patients across Europe.
- Accelerating research and ensuring access to orphan drugs for rare diseases.
Labour and social protection policies and primary health careHealth and Labour
Presentation by dr. Igor FEDOTOV, Coordinator, Occupational and Environmental Health, ILO Progamme SAFEWORK,Geneva, at the WHO/TNO/Dutchgovernment Congres 'Connecting Health and Labour' 29 - 1 December 2012
Presentation given by Elke Schneider (EU-OSHA) to the Conference 'Europe at a crossroads. Which way to quality jobs and prosperity?' held under the joint auspices of the European Trade Union Confederation (ETUC) and the European Trade Union Institute (ETUI) held in Brussels on 24-26 September 2014.
The document discusses the European Observatory on Health Systems and Policies, outlining its central principles, partnerships, governance, and core mission. The key points are:
1. The Observatory's central principles are to provide comparative analysis of health systems and policies, bridge the gap between evidence and policymaker needs, and develop practical policy options.
2. Partnerships with organizations like WHO and academic institutions are key to bridging this gap and ensuring research is relevant and accessible to policymakers.
3. Governance involves steering committees, independent academic directors, and a dedicated secretariat overseen by WHO.
4. The core mission is supporting evidence-based health policymaking through comprehensive analysis of European health systems,
The document discusses the European Observatory on Health Systems and Policies, outlining its central principles, partnerships, governance, and core mission. The key points are:
1. The Observatory's central principles are to provide comparative analysis of health systems and policies, bridge the gap between evidence and policymaker needs, and develop practical policy options.
2. Partnerships with organizations like WHO and academic institutions are key to bridging this gap and ensuring research is relevant and accessible to policymakers.
3. Governance involves steering committees, independent academic directors, and a dedicated secretariat to ensure credibility and quality.
4. The core mission is supporting evidence-based health policymaking through comprehensive analysis of European health systems
This document provides guidelines for workplace interventions to address psychoactive substance use. It recommends comprehensive interventions at workplaces that promote health, prevent accidents, and support employees. Interventions should include raising awareness, assessing workplace policies, brief interventions, referral systems, testing when appropriate, and ensuring confidentiality. The workplace is a convenient access point for health promotion given that most adults spend significant time at work. Prevention, identification, counseling, treatment and rehabilitation should be part of a systematic approach to address psychoactive substance harms in a way that also benefits families and communities.
The document discusses the regulatory environment for medicines in Ireland and Europe. It outlines how the Irish Medicines Board operates within the European system, providing resources to the European Medicines Agency and participating in evaluation, supervision, and inspection. It also discusses the IMB's international involvement, including partnerships with other agencies and participation in initiatives to enhance public health protection globally. Finally, it evaluates factors that contribute to the IMB becoming a "world-class" regulatory body.
The German Plan for Rare Diseases is a work in progress to improve care for those living with rare diseases in Germany. The document discusses that currently, rare diseases receive insufficient attention and care is fragmented across different healthcare sectors. It recommends developing a national coalition and plan to establish centers of expertise, improve guidelines and care coordination, and increase European collaboration. This coalition, called NAMSE, has begun work through working groups to develop a national plan and improve patient information, diagnostics, treatment guidelines and quality of care for those with rare diseases.
The document summarizes the development of national initiatives and European policies for rare diseases over the past few decades. It outlines key events and documents that have recognized rare diseases as a public health priority in Europe. These include the establishment of national plans and centers of expertise in many European countries between the 1980s-2000s, as well as European regulations, programs, and networks to support research, care, and access to orphan drugs. It discusses ongoing challenges and priorities for further developing strategies and cross-national collaboration to improve quality of life for those affected by rare diseases.
The document summarizes the development of national initiatives and European policies for rare diseases over the past few decades. It outlines key events and documents that have recognized rare diseases as a public health priority in Europe requiring transnational cooperation. These include the establishment of national plans and centers of expertise in many European countries from the 1980s onward, as well as European regulations, recommendations, and programs to support research, care coordination, and patient organizations. However, it notes ongoing challenges around decentralization, resources, and sustainability that require continued supportive policies.
The European Commission views patient safety as a priority and has taken several steps to promote it. These include establishing a patient safety working group, funding projects like EUNetPaS, and adopting a recommendation that encourages member states to develop national patient safety policies, empower patients, establish reporting systems, promote a culture of safety, and conduct research. While progress has been made, more work is still needed at the member state level, and the EU aims to play a supportive role through knowledge sharing, best practices, and continued coordination across Europe.
This document advertises the 10th annual conference of the Guidelines International Network (G-I-N) being held in Berlin. The conference will celebrate G-I-N's 10 years of international collaboration on clinical practice guidelines and discuss lessons learned and future visions. Plenary sessions will address topics like guideline methodology, the effects of guidelines on healthcare quality and outcomes, and patient involvement in guideline development. Pre-conference courses are also offered on guideline development, implementation, the GRADE approach, and health economics. A German language symposium will discuss guideline-related issues in German-speaking countries.
Thematic Platform for Emergency and Disaster Risk Management Health and the ...Global Risk Forum GRFDavos
Presentation at the Consultion Day event about: Scientific and Technical Platforms / Networks: Achievements and Future Goals during the Global Platform for Disaster Risk Reduction GPDRR 2013 in Geneva
Similar to Schwarzwaelder European Guide To Prevention In The Healthcare Sector (20)
LinkedIn for Your Job Search June 17, 2024Bruce Bennett
This webinar helps you understand and navigate your way through LinkedIn. Topics covered include learning the many elements of your profile, populating your work experience history, and understanding why a profile is more than just a resume. You will be able to identify the different features available on LinkedIn and where to focus your attention. We will teach how to create a job search agent on LinkedIn and explore job applications on LinkedIn.
LinkedIn Strategic Guidelines for June 2024Bruce Bennett
LinkedIn is a powerful tool for networking, researching, and marketing yourself to clients and employers. This session teaches strategic practices for building your LinkedIn internet presence and marketing yourself. The use of # and @ symbols is covered as well as going mobile with the LinkedIn app.
Khushi Saini, An Intern from The Sparks Foundationkhushisaini0924
This is my first task as an Talent Acquisition(Human resources) Intern in The Sparks Foundation on Recruitment, article and posts.
I invitr everyone to look into my work and provide me a quick feedback.
6. Stephan Schwarzwaelder The project team Partner Task Federal Institute for Occupational Health and Safety, Germany (BAuA) Project Management Contec Project Management Employer's Liability Insurance Association for Health and Welfare Services (BGW) Biological risks, musculo-skeletal risks, psychosocial risks, chemical risks BAD/TeamPrevent Group Workshop with hospitals from EU-Memberstates Support for biological risks, musculo-skeletal risks, psychosocial risks, chemical risks German Network for Health Promoting Hospitals (DNGfK) Workshop with hospitals from Germany
11. Structure of the guide – risk assessment in 5 steps Stephan Schwarzwaelder Step 1 – Identifying hazards and those at risk Step 2 – Evaluating and prioritising risks Step 5 – Documentation, monitoring and review Step 4 – Taking action Step 3 – Deciding on preventive action – T-O-P
12.
13. Description of good company practice Stephan Schwarzwaelder Preventing needlestick-injuries Ergonomically designed counter at a children centre
15. Link lists – further information and tools Stephan Schwarzwaelder Practical Guidlines: Chemical Agents Directive 98/24/EC
16.
17. European guide - European Expert Group Stephan Schwarzwaelder Participants from 12 Member States Focus: What do we have in common – not on the national differences Austria Germany Netherlands Belgium Greece Poland Bulgaria Hungary Portugal Cyprus Ireland Romania Czech Republic Italy Slovakia Denmark Latvia Slovenia Estonia Lithuania Spain Finland Luxembourg Sweden France Malta United Kingdom